BUZZ-Denali Therapeutics slides after launching $200 million share sale

Reuters12-10
BUZZ-Denali <a href="https://laohu8.com/S/LENZ">Therapeutics</a> slides after launching $200 million share sale

** Drug developer Denali Therapeutics' DNLI.O shares slide 9% to $17.90 in extended trading

** DNLI kicks off public offering of $200 million worth of shares and pre-funded warrants

** Goldman Sachs, J.P. Morgan Securities, Morgan Stanley and Jefferies are joint book-running managers for offering

** Proceeds will be used to advance commercial readiness and regulatory pathways for its drug pipeline, scale internal manufacturing capabilities, among other purposes

** DNLI has 146.6 million outstanding shares as of September 30, according to prospectus

** All 18 brokerages covering the stock rate it "buy" or higher; median PT $32 - data compiled by LSEG

** As of last close, DNLI stock down 3.5% YTD

(Reporting by Arasu Kannagi Basil in Bengaluru)

((ArasuKannagi.Basil@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment